Navigation Links
CutisPharma Launches New Prescription Mouthwash Kit Adding to Product Line
Date:9/22/2009

WOBURN, Mass., Sept. 22 /PRNewswire/ -- CutisPharma, Inc. announced the introduction of FIRST(R) - BXN Mouthwash. It is the second in the FIRST(R) Mouthwash Compounding Kit product line, which already includes FIRST(R) - Mouthwash BLM. The active ingredients in FIRST(R) - BXN Mouthwash are comparable to those found in the most routinely prepared formulation of Magic Mouthwash containing Benadryl(R), Xylocaine 2% viscous(R), and nystatin. The kits are made for one patient and include pre-weighed diphenhydramine hydrochloride, lidocaine hydrochloride, and nystatin powder, and a pre-measured suspension. With FIRST(R) - BXN Mouthwash, the pharmacist needs only to add the powders to the liquid suspension, shake, and then dispense to the patient.

"By launching FIRST(R) - BXN, physicians now have two of the more commonly prescribed magic mouthwash prescriptions available in a kit," said Dr. Indu Muni, founder, chairman, and CEO of CutisPharma, Inc. "The Company anticipates launching two additional Mouthwash products, FIRST(R) - Mary's Mouthwash, and FIRST(R) - Duke's Mouthwash, in the near future, thus completing the Mouthwash product line."

FIRST(R) products save dispensing time, and can be compounded by the pharmacist while the patient waits, increasing customer satisfaction. Using FIRST(R) Mouthwash kits, the pharmacist can compound a prescription faster than those prepared in the conventional way. A single NDC number assigned for the entire Kit facilitates the third party reimbursement process, and reduces audit- related adjustments.

CutisPharma now has ten proprietary prescription compounding kits on the market: five progesterone suppository compounding kits, two testosterone kits, one hydrocortisone kit, and two Magic Mouthwash kits. Several more compounding kits are in the planning stages. FIRST((R)) Unit-of-Use Prescription Compounding Kits comply with United States Pharmacopeia (USP) Chapter <795>.

The FDA estimates that each year in the United States approximately 30 million retail and hospital outpatient prescriptions are prepared through "compounding," a means by which a pharmacist prepares a customized medication according to a doctor's prescription to meet an individual patient's medical need. About 1% of all prescriptions are compounded; and the U.S. market alone for compounding, at the consumer level, represents an estimated $1 billion annually.

About CutisPharma

CutisPharma, Inc. based in Woburn, MA, is a privately held, specialty pharmaceutical company focusing on the development and commercialization of value-added proprietary drug products and technologies in the prescription compounding sector of the pharmaceutical industry. Product line and development efforts initially are focused on providing optimized, more efficient alternatives for the preparation of the nearly 10 million currently compounded prescriptions, by offering FIRST(R) Unit-of-Use Prescription Compounding Kits. Use of these branded compounding kits will be beneficial to all triad participants, namely physicians, pharmacists, and patients. Two U.S. patents have been issued to the Company with several additional patents pending.

For more information please visit our website at www.cutispharma.com


'/>"/>
SOURCE CutisPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. RESOLVE: The National Infertility Association Announces Partnership With CutisPharma
2. CutisPharma Announces Issuance of a Patent for Suppository Compounding
3. CutisPharma Announces Strategic Collaboration with Rite Aid Corporation
4. CutisPharma Selected by Medicine Shoppe International as Preferred Vendor for Unit-of-Use Compounding Kits
5. MEDISON Launches New Dedicated OB/GYN 3D/4D Ultrasound System, ACCUVIX V20 Prestige
6. Webmedx Launches New Data-Mining Solution for Medical Transcription and Speech-Generated Documents
7. World Health Organization Launches New Attack on Lung Cancer
8. Thomson Reuters Launches Thomson Pharma Partnering Forecast
9. https://happier.com/form.htmhappier.com Launches a Personal Trainer for Your Happiness
10. American Lung Association Launches Retro Marketing Initiative to Support 2009 Christmas Seals(R) Campaign
11. LYSOL(R) Launches Healthier Habits Rewards Program at Schools Nationwide to Help Protect Families from Germs, Such as H1N1
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2017)... ... July 22, 2017 , ... More than 130,000 Anterior Cruciate ... requiring pain medication after three months post-operatively. However, researchers presenting their work at ... Toronto, Ontario, Canada found that those patients who were filling opioid prescriptions prior ...
(Date:7/21/2017)... ... July 21, 2017 , ... The Wettstein Agencies, ... communities in the greater Denver region, is announcing a charity drive to help ... rare kind of epilepsy. , Until a few months ago, Dominik was a ...
(Date:7/21/2017)... Minnesota (PRWEB) , ... July 21, 2017 , ... ... BWBR recently were selected to renovate and improve the Ramsey County Medical Examiners ... adjacent to Regions Hospital, the $2.5 million project is scheduled to start in ...
(Date:7/21/2017)... ... July 21, 2017 , ... Bernard R. Bach, Jr., MD, ... the American Orthopaedic Society of Sports Medicine (AOSSM) , received the 2017 Robert ... Annual Meeting in Toronto, Canada. This prestigious award is given annually to honor those ...
(Date:7/21/2017)... ORLEANS, La. (PRWEB) , ... July 21, 2017 ... ... to allow 4th-year medical students improve their chances of acceptance to a residency ... for those who have earned degrees outside the U.S. , According to data ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... 2017  Sysmex America, Inc., a leading provider ... as well as middleware information systems technology, today ... quality assurance easier and more risk free than ... for the innovation that it delivers to the ... assurance processes to a new level with automated, ...
(Date:7/11/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ... on the development of oral drug delivery systems, announced ... has agreed to schedule an End-of-Phase II meeting with ... its oral insulin capsule ORMD-0801 in the treatment of ... and secondary endpoints by indicating a statistically significant lowering ...
(Date:7/10/2017)... The Institute for In Vitro Sciences (IIVS), ... of a VITROCELL® inhalation exposure system thanks to a ... device, which is designed to replace animals in inhalation ... to airborne test materials in an environment that mimics ... for testing combustible tobacco products, as well as next ...
Breaking Medicine Technology: